{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:52:30Z","timestamp":1789836750628,"version":"4.0.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["CIHR-425772"],"award-info":[{"award-number":["CIHR-425772"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>Several antihypertensive drugs are available for the primary prevention of cardiovascular disease (CVD). However, existing evidence on prescription patterns was primarily generated among patients at high CVD risk with short-term follow-up, and failed to capture impacts of time and patient characteristics. Our objective was therefore to describe longitudinal prescription patterns for antihypertensive drugs for the primary prevention of CVD among patients with arterial hypertension in the United Kingdom.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>This population-based cohort study used data from the Clinical Practice Research Datalink, included 660,545 patients with hypertension who initiated an antihypertensive drug between 1998 and 2018. Antihypertensive treatments were measured by drug class and described overall and in subgroups, focusing on first-line therapy (first antihypertensive drug(s) recorded after a diagnosis of hypertension) and second-line therapy (antihypertensive drug(s) prescribed as part of a treatment change following first-line therapy).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Angiotensin-converting enzyme (ACE) inhibitors (29.0%), thiazide diuretics (22.1%), and calcium-channel blockers (CCBs) (21.0%) were the most prescribed first-line therapies. ACE inhibitors have been increasingly prescribed as first-line therapy since 2001. Men were more likely to be prescribed ACE inhibitors than women (43.5% vs. 32.1%; difference: 11.4%; 95% confidence interval [CI], 11.0%\u201311.8%), and Black patients were more likely to be prescribed CCBs than White patients (63.6% vs. 37.0%; difference: 26.6%; 95% CI, 24.8%\u201328.4%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Antihypertensive prescription patterns for the primary prevention of CVD among patients with hypertension are consistent with treatment guidelines that were in place during the study period, providing reassurance regarding the use of evidence-based prescribing.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajh\/hpab137","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T14:11:13Z","timestamp":1630073473000},"page":"42-53","source":"Crossref","is-referenced-by-count":23,"title":["Prescription Patterns for the Use of Antihypertensive Drugs for Primary Prevention Among Patients With Hypertension in the United Kingdom"],"prefix":"10.1093","volume":"35","author":[{"given":"Tianze","family":"Jiao","sequence":"first","affiliation":[{"name":"Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital , Montreal, Quebec , Canada"},{"name":"Department of Epidemiology, Biostatistics and Occupational Health, McGill University , Montreal, Quebec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W","family":"Platt","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital , Montreal, Quebec , Canada"},{"name":"Department of Epidemiology, Biostatistics and Occupational Health, McGill University , Montreal, Quebec , Canada"},{"name":"Department of Pediatrics, McGill University , Montreal, Quebec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6005-4006","authenticated-orcid":false,"given":"Antonios","family":"Douros","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital , Montreal, Quebec , Canada"},{"name":"Department of Epidemiology, Biostatistics and Occupational Health, McGill University , Montreal, Quebec , Canada"},{"name":"Institute of Clinical Pharmacology and Toxicology, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin , Berlin , Germany"},{"name":"Department of Medicine, McGill University , Montreal, Quebec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6055-0088","authenticated-orcid":false,"given":"Kristian B","family":"Filion","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital , Montreal, Quebec , Canada"},{"name":"Department of Epidemiology, Biostatistics and Occupational Health, McGill University , Montreal, Quebec , Canada"},{"name":"Department of Medicine, McGill University , Montreal, Quebec , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,27]]},"reference":[{"key":"2022100812030906400_CIT0001","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics\u20142019 update: a report from the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"2022100812030906400_CIT0002","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.cjca.2018.02.022","article-title":"Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children","volume":"34","author":"Nerenberg","year":"2018","journal-title":"Can J Cardiol"},{"key":"2022100812030906400_CIT0003","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s40266-018-0580-0","article-title":"Antihypertensive treatment patterns and blood pressure control in older adults: results from the Berlin Aging Study II","volume":"35","author":"K\u00f6nig","year":"2018","journal-title":"Drugs Aging"},{"key":"2022100812030906400_CIT0004","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1161\/HYPERTENSIONAHA.116.07720","article-title":"Trends in antihypertensive medication discontinuation and low adherence among Medicare beneficiaries initiating treatment from 2007 to 2012","volume":"68","author":"Tajeu","year":"2016","journal-title":"Hypertension"},{"key":"2022100812030906400_CIT0005","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/HYPERTENSIONAHA.120.15462","article-title":"Treatment patterns and blood pressure control with initiation of combination versus monotherapy antihypertensive regimens","volume":"77","author":"An","year":"2021","journal-title":"Hypertension"},{"key":"2022100812030906400_CIT0006","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022100812030906400_CIT0007","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.cjca.2017.03.005","article-title":"Hypertension Canada\u2019s 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults","volume":"33","author":"Leung","year":"2017","journal-title":"Can J Cardiol"},{"key":"2022100812030906400_CIT0008","author":"National Institute for Health and Care Excellence"},{"key":"2022100812030906400_CIT0009","author":"National Institute for Health and Care Excellence"},{"key":"2022100812030906400_CIT0010","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/ije\/dyv098","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD)","volume":"44","author":"Herrett","year":"2015","journal-title":"Int J Epidemiol"},{"key":"2022100812030906400_CIT0011","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2125.2009.03537.x","article-title":"Validation and validity of diagnoses in the General Practice Research Database: a systematic review","volume":"69","author":"Herrett","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"2022100812030906400_CIT0012","doi-asserted-by":"crossref","first-page":"f2350","DOI":"10.1136\/bmj.f2350","article-title":"Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study","volume":"346","author":"Herrett","year":"2013","journal-title":"BMJ"},{"key":"2022100812030906400_CIT0013","doi-asserted-by":"crossref","first-page":"e010210","DOI":"10.1136\/bmjopen-2015-010210","article-title":"Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study","volume":"6","author":"Sharma","year":"2016","journal-title":"BMJ Open"},{"key":"2022100812030906400_CIT0014","doi-asserted-by":"crossref","first-page":"j2099","DOI":"10.1136\/bmj.j2099","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study","volume":"357","author":"Hippisley-Cox","year":"2017","journal-title":"BMJ"},{"key":"2022100812030906400_CIT0015","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/aje\/kwp425","article-title":"Multiple imputation for missing data: fully conditional specification versus multivariate normal imputation","volume":"171","author":"Lee","year":"2010","journal-title":"Am J Epidemiol"},{"key":"2022100812030906400_CIT0016","doi-asserted-by":"crossref","first-page":"b2393","DOI":"10.1136\/bmj.b2393","article-title":"Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls","volume":"338","author":"Sterne","year":"2009","journal-title":"BMJ"},{"key":"2022100812030906400_CIT0017","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/sj.jhh.1000917","article-title":"Guidelines for management of hypertension: report of the third working party of the British Hypertension Society","volume":"13","author":"Ramsay","year":"1999","journal-title":"J Hum Hypertens"},{"key":"2022100812030906400_CIT0018","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3399\/bjgp12X630232","article-title":"Management of hypertension in adults in primary care: NICE guideline","volume":"62","author":"McCormack","year":"2012","journal-title":"Br J Gen Pract"},{"key":"2022100812030906400_CIT0019","doi-asserted-by":"crossref","first-page":"7329","DOI":"10.1073\/pnas.1510502113","article-title":"Characterizing treatment pathways at scale using the OHDSI network","volume":"113","author":"Hripcsak","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022100812030906400_CIT0020","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"2022100812030906400_CIT0021","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","article-title":"Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial","volume":"292","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"2022100812030906400_CIT0022","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/01.hjh.0000160223.94220.29","article-title":"Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial","volume":"23","author":"Lubsen","year":"2005","journal-title":"J Hypertens"},{"key":"2022100812030906400_CIT0023","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1291\/hypres.28.385","article-title":"Blood pressure reduction and cardiovascular prevention: an update including the 2003\u20132004 secondary prevention trials","volume":"28","author":"Staessen","year":"2005","journal-title":"Hypertens Res"},{"key":"2022100812030906400_CIT0024","author":"Centre NP"},{"key":"2022100812030906400_CIT0025","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s12913-015-1013-y","article-title":"The impact of the \u2018Better Care Better Value\u2019 prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design","volume":"15","author":"Baker","year":"2015","journal-title":"BMC Health Serv Res"},{"key":"2022100812030906400_CIT0026","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1001\/jama.290.21.2805","article-title":"A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial","volume":"290","author":"Pepine","year":"2003","journal-title":"JAMA"},{"key":"2022100812030906400_CIT0027","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial","volume":"353","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"2022100812030906400_CIT0028","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"Lancet"},{"key":"2022100812030906400_CIT0029","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"key":"2022100812030906400_CIT0030","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200003303421301","article-title":"Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study","volume":"342","author":"Gress","year":"2000","journal-title":"N Engl J Med"},{"key":"2022100812030906400_CIT0031","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","article-title":"Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis","volume":"369","author":"Elliott","year":"2007","journal-title":"Lancet"},{"key":"2022100812030906400_CIT0032","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1001\/jama.293.13.1595","article-title":"Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril","volume":"293","author":"Wright","year":"2005","journal-title":"JAMA"},{"key":"2022100812030906400_CIT0033","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/HYPERTENSIONAHA.110.152892","article-title":"Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement","volume":"56","author":"Flack","year":"2010","journal-title":"Hypertension"},{"key":"2022100812030906400_CIT0034","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/EDE.0000000000000088","article-title":"ACE inhibitors and urinary tract infections","volume":"25","author":"Pouwels","year":"2014","journal-title":"Epidemiology"},{"key":"2022100812030906400_CIT0035","doi-asserted-by":"crossref","first-page":"169S","DOI":"10.1378\/chest.129.1_suppl.169S","article-title":"Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines","volume":"129","author":"Dicpinigaitis","year":"2006","journal-title":"Chest"},{"key":"2022100812030906400_CIT0036","doi-asserted-by":"crossref","first-page":"e2025127","DOI":"10.1001\/jamanetworkopen.2020.25127","article-title":"Association of race\/ethnicity-specific changes in antihypertensive medication classes initiated among Medicare beneficiaries with the eighth joint National Committee Panel Member Report","volume":"3","author":"Colvin","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2022100812030906400_CIT0037","author":"Government of UK"},{"key":"2022100812030906400_CIT0038","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/pubmed\/fdt116","article-title":"Completeness and usability of ethnicity data in UK-based primary care and hospital databases","volume":"36","author":"Mathur","year":"2014","journal-title":"J Public Health (Oxf)"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajh\/advance-article-pdf\/doi\/10.1093\/ajh\/hpab137\/40442019\/hpab137.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/35\/1\/42\/46383010\/hpab137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/35\/1\/42\/46383010\/hpab137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T12:05:13Z","timestamp":1665230713000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/35\/1\/42\/6358515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,27]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,8,27]]},"published-print":{"date-parts":[[2022,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpab137","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,8,27]]}}}